Literature DB >> 7969203

Subcortical neurofibrillary degeneration presenting as Steele-Richardson-Olszewski and other related syndromes: a review of 90 pathologically verified cases.

V M De Bruin1, A J Lees.   

Abstract

We have reviewed 90 patients from the literature with histopathological features compatible with currently accepted criteria for the diagnosis of the Steele-Richardson-Olszewski syndrome (SROS). Only 62 patients (69%) had clinically definite SROS based on the criteria of Maher and Lees. Neurofibrillary degeneration of subcortical structures with involvement of the internal pallidum, the subthalamic nucleus, and substantia nigra was considered essential for the pathological diagnosis. Thirty-six cases (40%) had neocortical neurofibrillary change that bore no clear relationship to the degree of cognitive impairment (chi 2 = 9.293; p < 0.4107). Grumose degeneration of the dentate nucleus was present in 25 cases (28%), and occasionally there were other, less usual, findings such as Pick bodies and Lewy bodies.

Entities:  

Mesh:

Year:  1994        PMID: 7969203     DOI: 10.1002/mds.870090402

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  4 in total

Review 1.  Progressive supranuclear palsy.

Authors:  H U Rehman
Journal:  Postgrad Med J       Date:  2000-06       Impact factor: 2.401

2.  Dystonia in progressive supranuclear palsy.

Authors:  C L Barclay; A E Lang
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-04       Impact factor: 10.154

3.  Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.

Authors:  I Litvan; C A Mangone; A McKee; M Verny; A Parsa; K Jellinger; L D'Olhaberriague; K R Chaudhuri; R K Pearce
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

Review 4.  How to spot ocular abnormalities in progressive supranuclear palsy? A practical review.

Authors:  Onanong Phokaewvarangkul; Roongroj Bhidayasiri
Journal:  Transl Neurodegener       Date:  2019-07-10       Impact factor: 8.014

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.